Sensus Blog

The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.

June
09
2026

Is There an Alternative to Mohs Surgery for Non-Melanoma Skin Cancer?

Receiving a non-melanoma skin cancer diagnosis can feel stressful. In fact, studies show that more than one in three patients find the diagnosis traumatic, with many more experiencing anxiety about what comes next. For many,…

August
02
2018

Sensus Healthcare Receives FDA 501(k) Clearance to Market Next-Generation SRT-100+ Superficial Radiation Therapy for Treating Non-Melanoma Skin Cancer and Keloids

SRT-100+ Offers Advanced Features for Patients and Doctors, Including Remote Diagnostics and Patient Medical Records Integration, as Well as Core System Enhancements BOCA RATON, Fla., Aug. 2, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a…

August
02
2018

Sensus Healthcare Receives FDA 501(k) Clearance to Market Next-Generation SRT-100+ Superficial Radio Therapy for Treating Non-Melanoma Skin Cancer and Keloids

SRT-100+ Offers Advanced Features for Patients and Doctors, Including Remote Diagnostics and Patient Medical Records Integration, as Well as Core System Enhancements BOCA RATON, Fla., Aug. 2, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a…

August
01
2018

5CC in Barcelona

Join Sensus Healthcare at the 5-Continent-Congress (5CC) in Barcelona, Spain August 30th – September 2nd, 2018. For tickets and more information click here.

July
31
2018

Sensus Healthcare CEO Receives “Innovator of the Year” Award at The Aesthetic Show 2018

BOCA RATON, Fla., July 31, 2018,/PRNewswire/ — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radio Therapy (IGSRT), today…

Archives
Archives

IN THE NEWS

From Scalpel to SRT: Impact of Innovation on the Dermatology Industry